Therefore, it has been suggested that gonadotropin-releasing hormone injection, aromatase inhibitor, or selective progesterone receptor modulator can be used for conservative or primary treatment of young women with reproductive desire and prevention of postoperative recurrence.[19–22] The efficacy and safety of such drugs in LPD patients need to be confirmed by further clinical case studies due to lack of clinical evidence. This evidence concerns the gene CYP19A1 and disseminated peritoneal leiomyomatosis.